Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab in the Treatment of Advanced Renal Cancer

NCT07877194 is registered in ClinicalTrials.gov with Summit Therapeutics as lead sponsor.

NCT NCT07877194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07877194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab in the Treatment of Advanced Renal Cancer
Lead sponsor
Summit Therapeutics
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 19, 2026
Completion date
December 12, 2029
Enrollment
100 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma, clear cell